Johnson & Johnson to acquire Auris Health for about $3.4B in cash
Johnson & Johnson announced that Ethicon entered into a definitive agreement to acquire Auris Health for approximately $3.4B in cash. Additional contingent payments of up to $2.35B, in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health is a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. This acquisition will accelerate Johnson & Johnson's entry into robotics with potential for growth and expansion into other interventional applications. With this acquisition, Frederic Moll, M.D., CEO and Founder of Auris Health and a visionary in the field of surgical robotics, will be joining Johnson & Johnson upon completion of this transaction. The closing is subject to antitrust clearance and other customary closing conditions. The transaction is expected to close by the end of the second quarter of 2019. The company will discuss the transaction further during its next quarterly earnings call on April 16.